Mast Therapeutics, Inc. (SVRA) Stock Rating Upgraded by Zacks Investment Research
Mast Therapeutics, Inc. (NASDAQ:SVRA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm presently has a $6.75 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 4.65% from the stock’s previous close.
According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
Separately, Canaccord Genuity started coverage on Mast Therapeutics in a report on Wednesday, June 7th. They issued a “buy” rating and a $18.00 price target for the company.
Mast Therapeutics (SVRA) opened at 6.45 on Friday. The stock’s market cap is $156.11 million. Mast Therapeutics has a 12 month low of $4.60 and a 12 month high of $49.62. The firm has a 50-day moving average price of $5.70 and a 200-day moving average price of $5.87.
ILLEGAL ACTIVITY WARNING: “Mast Therapeutics, Inc. (SVRA) Stock Rating Upgraded by Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/08/mast-therapeutics-inc-svra-stock-rating-upgraded-by-zacks-investment-research.html.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.